3SOF

Even though this is only a 50c stock, technicals still apply. The double bottom low of 43c should provide enough of a support level here, combined with positive fund'l news, and this stock should be able to pivot right here from this higher low, and vault over the 50 dayMA finally. Perhaps this will force the shorties to cover their (probably unborrowed) shares (plus tax loss selling will abate soon), and we could see $1+ .

http://clearstation.etrade.com/cgi-bin/details?Symbol=nvlt&Refer=http://clearstation.etrade.com/

http://biz.yahoo.com/bw/071217/20071217005512.html?.v=1

http://stockcharts.com/h-sc/ui?s=NVLT&p=D&yr=0&mn=6&dy=0&id=p32788104657

another 6% friday

http://stockcharts.com/h-sc/ui?s=NVLT&p=D&yr=0&mn=6&dy=0&id=p32788104657

up 11% today

http://stockcharts.com/h-sc/ui?s=NVLT&p=D&yr=0&mn=6&dy=0&id=p32788104657

more tommorrow

http://stockcharts.com/h-sc/ui?s=NVLT&p=D&yr=0&mn=6&dy=0&id=p32788104657

http://stockcharts.com/h-sc/ui?s=NVLT&p=D&yr=0&mn=6&dy=0&id=p32788104657

another white candle

http://stockcharts.com/h-sc/ui?s=NVLT&p=D&yr=0&mn=6&dy=0&id=p32788104657

double bottom. let the games begin

http://stockcharts.com/h-sc/ui?s=nvlt&p=D&b=5&g=0&id=0

looks like we will be off to the races tommorrow

http://stockcharts.com/h-sc/ui?s=nvlt&p=D&b=5&g=0&id=0

another good day

http://stockcharts.com/h-sc/ui?s=nvlt&p=D&b=5&g=0&id=0

and again

http://stockcharts.com/h-sc/ui?s=nvlt&p=D&b=5&g=0&id=0

chugging along nicely

another 10% today

another great day today.
NVLT.ob

Not a bad day today. Showing an SAR parabolic bullish signal.

So why the 20M and change market cap? Good question. Just as an example, CYTR (Nasdaq) has a Pipeline of: 2 phase II's, 1 phase I and numerous preclinicals, and has a market cap of 325 M.  NVLT is heavily discounted.

Good Luck

looking interesting

http://stockcharts.com/h-sc/ui?s=nvlt&p=D&b=5&g=0&id=0

-Rodman and Renshaw values the company at 200M. Its current market cap is 20M.

Novelos (NVLT.ob) is dramtically undervalued relative to other early stage biotechs. As an example, CYTR (Nasdaq) has a Pipeline of: 2 phase II's, 1 phase I and numerous preclinicals, and has a market cap of 325 M. As soon as the investment community acknowledges the potential for Novelos to develop a portfolio of active Glutathione derivatives against a broad spoectrum of diseases, the market cap should rise accordingly.

Projections: Rodman and Renshaw recently assigned a risk adjusted NPV for NOV-002 of 200M, which I beleive, at this time, is a low estimate. For example, they gave only a 40% probabilty of success as part of the NPV analysis of NOV-002 for NSCLC. This is despite the drug candidate already receiving positive Phase II results in the Russian study and now also in the US. As a point of reference here, as a drug moves through the pipeline and passes each hurdle, the risk decreases with each major milestone. Drugs entering Phase I clinical trials have a only a 15% probability of success. For phase II, the odds are around 30%, and for Phase III, 60%. Thus, if a probability of success of 60% was given, then the NPV becomes 300M, without any revenue from other cancer studies included at this time.